Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis.

@article{Lin2015ClinicalAS,
  title={Clinical and Safety Outcomes of Oral Antithrombotics for Stroke Prevention in Atrial Fibrillation: A Systematic Review and Network Meta-analysis.},
  author={Liang Lin and Wee Shiong Lim and Hui Zhou and Ai Leng Khoo and K. T. Tan and Aik Phon Chew and David Chee Guan Foo and Jing Jih Chin and Boon Peng Lim},
  journal={Journal of the American Medical Directors Association},
  year={2015},
  volume={16 12},
  pages={1103.e1-19}
}
INTRODUCTION Novel oral anticoagulants (NOACs) expanded the options for stroke prevention in atrial fibrillation (AF). Earlier studies comparing their relative effectiveness and safety typically do not incorporate age-related differences or postmarketing studies. This study aimed to summarize and compare clinical and safety outcomes of oral antithrombotics for stroke prevention in AF in younger (65-74 years) and older (≥75 years) elderly. METHODS We searched PubMed, Embase, and The Cochrane… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 1 time. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Apixaban Inhibits Cerebral Microembolic Signals Derived from Carotid Arterial Thrombosis in Rabbits.

The Journal of pharmacology and experimental therapeutics • 2016
View 6 Excerpts
Highly Influenced

Challenges in comparing the non-vitamin K antagonist oral anticoagulants for atrial fibrillation-related stroke prevention.

Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology • 2018

Similar Papers

Loading similar papers…